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ABBREVIATIONS 
 
aPCC = activated prothrombin complex concentrates 
DCA = Discrete Choice Analysis 
DCE = Discrete Choice Experiment 
FVIII = factor VIII 
ITI = immune tolerance induction 
HRQoL = health related quality of life 
MRS = marginal rates of substitution 
NHS = National Health Service 
PCC = prothrombin complex concentrates 
QoL = Quality of Life 
RUT = Random Utility Theory 
rFVIIa = recombinant activated factor VII  
RI =Relative importance 
WTP = willingness to pay 
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SUMMARY 
 
Rationale  
Despite the success of recent investments in health technology for the treatment in 
hemophilic patients, today, inhibitor development is a major complication of hemophilia 
treatment, as inhibitors increase the risk of uncontrollable bleeding, make surgery more 
problematic, increase the risk of severe physical disabilities, reduce wellbeing, and represent 
a potential cause of premature mortality.  
The introduction of new options, such as immune tolerance induction and the use of 
bypassing agents, has significantly improved treatment success in inhibitor patients in even 
the most challenging situations (e.g. emergencies, home treatment, and surgery). However, 
these treatment advances are paralleled by significant increases in the cost of care for these 
patients, and economic constraints can cause limited access to optimal therapy.  In order to 
optimize the benefits derived from use of the available resources, it is necessary to know and 
compare both present and future effects and costs of alternative options. Identification of the 
most efficient option allows implementation of appropriate investments, which must be 
considered as opportunities to improve patients’ health and wellbeing. Implementing rational 
investments may also facilitate economic benefits in the future, with potential advantages not 
only for patients, but also for their families and for society as a whole.  
However, there is still a lack of consensus on how to optimally treat haemophilia 
patients with inhibitors. Considerable uncertainty remains about the optimum treatment 
choice in different clinical circumstances. Furthermore, in several healthcare systems, 
resource constraints are main potential obstacles for access to the most efficient treatment 
options. As a result, clinicians have for several years made decisions on how to manage their 
patients according to their own experience and opinions. These decisions can differ  
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depending on the type of patient, on the bleeding situation, and on possible considerations 
related to safety, immunogenicity, practicalities, product availability, and costs.  
The management of these patients actually involves a complex interaction between 
different parties, i.e. physicians, patients or their caregivers, and budget holders. Each of 
these parties has their own set of preferences, which is influenced by the role they play in the 
healthcare system, their experiences, and their expectations. In order to optimise the 
appropriateness of the decisions, it is necessary to be both informed and aware of the 
opinions and preferences of the interested parties. This knowledge can be useful in order to 
better understand the potential benefits of treatments, thereby improving the success, and 
possibly also increasing the efficiency, of the intervention. 
  
Objective  
This work aimed to evaluate preferences towards the characteristics of different 
coagulation factor concentrates for haemophilia inhibitors patients, from the perspective of 
patients or their caregivers, haematologists, pharmacists.  
 
Methods 
A discrete choice study was conducted. Potential products were described with eight 
selected characteristics: perceived viral safety, risk of anamnestic response, possibility of 
undergoing major surgery, frequency of infusions in prophylaxis, number of infusions to stop 
bleeding, time to stop bleeding, time to pain recovery, cost. Participants received 16 pairs of 
potential products and chose from each pair the option they considered better. Data were 
analyzed with a random-effects conditional logistic model.  
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Results 
1614 observations were obtained from 37 patients/caregivers, 39 physicians, and 25 
pharmacists from Italy. Cost, in terms of additional healthcare taxes, was the most important 
attribute to every group: the relative importance assigned to this characteristic was 21% by 
the patients/caregivers and 26-27% by the physicians and pharmacists, suggesting that unlike 
to what it may be thought, cost is an important issue also to people not directly involved in 
the payment for these products.  
For patients/caregivers the next most important factors were: risk of anamnestic 
response (RI = 20%), possibility of undergoing major surgery (RI = 18%), perceived viral 
safety (RI = 18%). For physicians the next most important characteristics were: risk of 
anamnestic response (RI = 18%), number of infusions to stop bleeding (RI = 14%), 
possibility of undergoing major surgery (RI = 13%). For pharmacists the next most important 
factors were: time to stop bleeding (RI almost 20%), time to pain recovery (R = 14%), 
possibility of undergoing major surgery (RI = 13%). 
 
Discussion 
To our best knowledge this is the first study estimating and comparing the value given 
by patients (or their caregivers), physicians, and pharmacists to the different characteristics of 
coagulation factor concentrates used for the treatment of haemophilia patients with inhibitors. 
Not only outcome attributes, such as those related to safety, like viral and risk of anamnestic 
response, those related to effectiveness, like the time to stop a bleeding, the time to alleviate 
the pain and possibility of undergoing major surgery, but also process attributes (frequency of 
infusions to stop a bleeding or to follow a prophylaxis regimen) and cost are considered 
important for a product used in patients with inhibitors.  
Decisions on treatments must take into account patients’ characteristics and their 
clinical needs; however, preferences can also play an important role in the choice and success 
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of treatments. The results of this study could, therefore, help decision-makers to optimise the 
overall benefits of treatments. 
 9
INTRODUCTION 
 
 The disease 
 
 Hemophilia is a rare disease due to inherited coagulation defects that cause 
spontaneous and post-traumatic bleeding. The prevalence of this disease in Italy has been 
established recording data provided by 35 hemophilia centers in a computerized national 
registry: hemophilia A affects 0.82/10,000 males in the general population, of which 64% are 
severely affected. Hemophilia B affects 0.15/10,000 males, of which 70% are severe [1]. In 
other Western countries, the estimated prevalence of hemophilia is similar to that in Italy [2, 
3]. In patients with hemophilia, bleeding and its complications in muscles and joints often 
lead to disability, extreme pain and impairment of the overall quality of life. In recent years 
the availability of more effective drugs has generally improved management of patients with 
hemophilia. Because of the cost of treatment and the complex nature of the disease that 
warrants a multisciplinary approach, the health care of patients with hemophilia absorbs a 
large amount of economical and human resources and can be taken as an example of the 
socio-economic impact of biotechnologies in rare diseases [4-6].  
 
Development of inhibitors against treatment with coagulation factor concentrates 
 
The development of inhibitory antibodies in hemophilic patients treated with clotting 
factor concentrates is one of the most challenging complications of hemophilia treatment, as 
it inactivates the coagulation factor activity, hence  compromises the efficacy of the mainstay 
of treatment, i.e., factor replacement [7].  
The overall prevalence of inhibitors in patients with hemophilia A or B is estimated to 
be approximately 9% and 3% respectively; patients with moderately severe (factor levels 1-
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5%) and severe hemophilia A (<1%) have a greater risk of developing inhibitors, with a 
reported prevalence between 7% and 20% [8-13].  
This complication makes the treatment of bleeding episodes more difficult, increases 
the risk of uncontrollable haemorrhages, and makes the performance of surgery more 
problematic, with important consequences in terms of disability, poor well-being, and 
premature death [9, 11, 12, 14-17]. 
Inhibitors predominantly develop in early childhood, during the initial phase of 
treatment with coagulation factor concentrates. Inhibitor development has been found to be 
related to a number of possible endogenous and exogenous factors such as genetic, 
ethnic/racial or family reasons, type and severity of haemophilia, exposure to replacement 
concentrates, and treatment regimen [8, 18-27].  
 
 Treatment of patients with inhibitors 
 
Special therapeutic approaches are used in inhibitor patients to reduce the antibody 
level [15, 28], such as the induction of immune tolerance [29, 30] and plasma exchange with 
or without immunoadsorption on protein A columns. Although the implementation of 
immune tolerance induction (ITI) has facilitated the eradication of inhibitors in a number of 
patients [16, 31], this approach is not actually efficacious in around 30-40% of cases [9, 32, 
33]. In addition, not all patients are considered suitable candidates for ITI: for example, 
patients with long-standing inhibitors, those with further difficulties with treatment, those at 
an increased risk of serious bleeding complications, and those with chronic joint diseases. 
Factor VIII (FVIII) derived from porcine plasma (porcine FVIII) with a lower antibody 
cross-reactivity, and agents bypassing the coagulation defect, such as prothrombin complex 
concentrates (PCC), activated prothrombin complex concentrates (aPCC) [10, 34, 35], and 
recombinant activated factor VII (rFVIIa) [36-38], have been successfully adopted in a 
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number of these challenging situations, including emergency, home treatment, and surgery 
[10, 28, 29, 35, 38-47], in which they contribute to prolonging patients’ life expectancy and 
improving health related quality of life (HRQoL) [48, 49]. 
 
According to recent data from a naturalistic Italian Cost of Care Inhibitors Study 
(named COCIS) [48], the current management of adult patients with inhibitors leads to 
relatively good levels of wellbeing. This study observed 52 patients (aged 15–64 years) for 
up to 18 months: their orthopedic condition was found to be compromised, with 73% of 
patients having impaired range of motion in at least one main joint (hip, knee, wrist). Other 
frequent signs or symptoms related to a compromised orthopedic functioning were crepitus 
(71.2% of the patients), flexion contractures (69.2%), and axial deformity (57.7%). 
Regarding HRQoL 63% reported difficulties in walking (as ascertained by the ‘mobility’ 
domain of the EQ-5D questionnaire [50]); 34% reported difficulties with taking care of 
themselves (e.g. washing or dressing); 54% reported difficulties with performing usual 
activities (e.g. work, study, housework, family or leisure activities); 78% had moderate or 
severe pain or discomfort; and 38% declared themselves to be moderately or severely 
anxious or depressed. HRQoL assessed with the SF-36 instrument [51, 52] was shown to be, 
on average, lower for inhibitor patients than for the general population comparable for age 
and sex. A relationship between inhibitor patients’ orthopedic functioning and the physical 
component of their HRQoL was also found [53], particularly for issues such as mobility, self-
care, daily activities and perception of pain and/or discomfort: problems in these domains 
were reported more frequently by patients with more compromised orthopedic functioning. In 
contrast, the mental component of wellbeing is not particularly affected by the presence of 
inhibitors, as no association was found with orthopedic problems. One interpretation of these 
findings is that, while chronic and irreversible orthopedic disabilities affect the physical 
health of inhibitor patients, the awareness that effective interventions are available allows 
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patients to cope well with their clinical condition and to preserve relatively good levels of 
mental QoL  
 
More recently, a naturalistic European study on the orthopedic status of patients with 
hemophilia and inhibitors (ESOS), conducted by Morfini and colleagues in several European 
countries [54], confirmed the relationship between orthopedic complications and QoL in 
inhibitor patients. Problems with mobility, self-care, performing usual activities, and 
pain/discomfort were reported more frequently by inhibitor patients, while there were no 
significant differences in the prevalence of anxiety and depression between inhibitor and non-
inhibitor patients. This study also found that patients with inhibitors typically have 
significantly more joint abnormalities, and consume more resources, than those without 
inhibitors.  
On the other hand, the management of hemophiliacs with inhibitors is particularly 
costly, both in absolute terms and in comparison with the treatment of hemophiliacs without 
inhibitors [55, 56]. Treatment cost is a major issue to be considered in hemophilia care, as 
significant increases in costs have paralleled advances in healthcare. For instance, the cost of 
treatment for adult patients with inhibitors corresponds to an average of around €200,000 per 
patient per year [49]– more than twice the mean cost of treatment for patients with moderate 
to severe hemophilia without inhibitors [57]. The majority of costs (99%) are attributable to 
the use of coagulation factor concentrates, while almost 50% is attributable to the use of  
rFVIIa, which is widely used to manage both spontaneous and surgical (including 
orthopedic) bleeding episodes. As a consequence, although effective strategies are currently 
available to meet inhibitor patients’ needs (e.g. management of bleeding, performance of 
orthopedic surgery), the huge amount of resources consumed in recent years actually limits 
use of the best available options in some healthcare systems [58-65]. 
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Of interest in this regard is what emerged from a discussion between US hemophilia 
care providers about the issues that influence treatment choices for high-titer inhibitor 
patients [64]. The cost and supply of bypassing agents were found to be critical determinants 
in choice of product for almost half the participating physicians. One panelist stated that his 
hospital dictated that rFVIIa could only be used after other treatment options had been 
exhausted. Furthermore, many physicians noted that their large public hospitals have 
established stringent rules for approval of rFVIIa use. 
 
Solimeno and colleagues [61] reported that, although total joint replacement is now 
the treatment of choice for hemophilia patients with chronic hemophilic arthropathy of the 
knee and hip in developed and developing countries, the same cannot yet be said for 
hemophilic patients with inhibitors: elective surgery in these patients today is still limited to a 
few centers and extremely few subjects. The availability of rFVIIa has allowed such 
procedures to be undertaken in inhibitor patients, but surgery remains uncommon because of 
the elevated costs of replacement therapy. 
 
Data from 13 economic studies were recently reviewed by Stephens and colleagues 
[60], and it was found that the costs of rFVIIa are incurred primarily during hospitalization to 
manage major bleeding and facilitate orthopedic surgery (which would not have been 
attempted prior to the advent of rFVIIa). Interestingly, according to the studies reported in 
this review, the authors noted that the total cost of treating a bleeding episode with rFVIIa 
may be lower than that associated with using plasma-based agents. This finding that may be 
attributable to faster bleed resolution, higher initial efficacy rates, and avoidance of second- 
and third-line treatment. 
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According to recent observations and expert opinion on the issue of healthcare in 
hemophilia complicated by inhibitors, it is widely agreed that the levels of health in inhibitor 
patients are still not optimal. The prevention and treatment of orthopedic disability must be 
considered a primary goal in efforts to improve overall wellbeing and reduce treatment costs 
in inhibitor patients.  
 
In 2006, Allen and Aledort reported the results of a panel discussion of therapeutic 
decision-making for patients with inhibitors [62]. The hematologists of the panel agreed that, 
when choosing treatment for each patient, there are a number of considerations to be taken 
into account with regard to safety, efficacy, and treatment costs. The authors of the report 
emphasized that treatment choice depends on an appropriate trade-off between different 
characteristics of the products according to such variables as patient characteristics and 
needs. In any case, there is still considerable uncertainty as to which therapeutic option is 
most appropriate in different clinical circumstances. The lack of data from comparative trials 
means that clinicians make the best treatment decisions possible based on their own 
experience, opinions and resources. Despite the best of intentions, treatment choices made in 
this way might not always result in provision of the best care. 
 
The European Haemophilia Therapy Standardisation Board stated that the 
management of patients with inhibitors will continue to be a major challenge in hemophilia 
care for many years. Bypassing products are available but expensive; therefore, their use is 
not an option for all patients. In addition, the hemostatic effect of such agents may vary in 
different individuals. Consequently, comparative studies between available treatment options 
and analyses to predict and monitor the effect of these agents are highly warranted in order to 
optimize their use [65]. 
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It is quite clear that mo consensus exists yet on the therapeutic strategy and products 
to use in order to improve the management of inhibitor patients. In addition, considerable 
uncertainty remains about the optimum treatment choice in different clinical circumstances 
[62, 65]. As a result, clinicians have for several years made decisions on how to manage their 
patients according to their own experience and opinions. These decisions can, however, differ 
depending on the type of patient, on the bleeding situation, and on possible considerations 
related to safety, immunogenicity, practicalities, product availability, and costs [49].  
 
The management of these patients actually involves a complex interaction between 
different parties, i.e. physicians, patients or their caregivers, and budget holders. Each of 
these parties has their own set of preferences, which is influenced by the role they play in the 
healthcare system, their experiences, and their expectations. In order to optimise the 
appropriateness of the decisions, it is necessary to be both informed and aware of the 
opinions and preferences of the interested parties. This knowledge can be useful in order to 
better understand the potential benefits of treatments, thereby improving the success, and 
possibly also increasing the efficiency, of the intervention. 
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OBJECTIVE  
 
This study was conducted with the objective of identifying and estimating the relative 
importance assigned to different characteristics of coagulation factor concentrates used to 
treat haemophilia patients with inhibitors. Preferences towards different possible coagulation 
factor concentrates were elicited from both patients’, physicians’ and pharmacists’ points of 
view. 
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METHODS 
 
Discrete Choice Analysis: technique overview 
 
To reach the study objective, the technique of Discrete Choice Analysis (DCA) was 
adopted.  
DCA is a technique for eliciting preferences, useful tool widely employed for 
estimating values of non-market goods and services. DCAs are based upon the idea that 
goods can be described by their characteristics (or attributes) and individuals’ preferences for 
these goods are dependent upon the levels of the attributes. 
DCAs were developed in mathematical psychology [66] and then applied in several 
different areas [67-71]. In the past 15 years [72] this technique has been increasingly used to 
elicit preferences for healthcare interventions and to allow inclusion of more than just health 
outcomes [73].  
In the haemophilia context it was recently applied for the first time [74] and allowed 
to shown that process attributes such as factor infusion frequency and mode of product 
distribution, in addition to safety and effectiveness, are considered important in haemophilia 
care. 
 
Within a DCA, hypothetical scenarios are created with combinations of previously 
selected attribute levels and are presented to participants who choose between a number of 
alternative options. As the DCA elicitation process consists of a trade-off between the 
attributes during the decision-making process, it has the potential to meet economic criteria 
for measuring benefit. Thus the technique is useful in conducting cost–benefit analyses, i.e. 
economic evaluations where different types of benefits can be included in one algorithm 
estimating the overall net benefit of alternative healthcare interventions. 
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DCAs make it possible to estimate whether an attribute is important, the relative 
importance of one attribute compared with the others, how individuals are willing to trade 
between different attributes, by estimating the marginal rates of substitution (MRS).  
The MRS describes the rate at which individuals are willing to give up units of one 
“good” or of one attribute in exchange for more units of another “good” or attribute. The 
inclusion of “cost” as an attribute facilitates the estimation of MRS in monetary terms, 
known as willingness to pay (WTP), which can be interpreted as an estimate of the relative 
values assigned to an attribute included in the choice set, or even to a product described 
according to these attributes, expressed in monetary terms. By expressing the value of the 
attributes or products in monetary terms it is furthermore interesting as it allows to better 
understand the magnitude of the relative importance assigned to them because it is expressed 
in a unique term, which people are in general familiar with and allowing direct comparisons 
between different factors.  
 
The study was conducted in four main phases: 1) study design – choosing the 
attributes, assigning levels to each attribute, and constructing the scenarios to be evaluated; 2) 
preparation of the survey instrument; 3) data collection; and 4) data analyses and 
interpretation of the results. 
 
Study design 
 
The basis for the DCA is the experimental design [75]: a Discrete Choice Experiment 
(DCE) is designed to obtain the scenarios that describe the potential products (or services) to 
be valued. A number of considerations, from both a statistical and a practical point of view 
were taken into account during the DCE design, with the objective of keeping a satisfying 
level of overall efficiency of the experiment [76], i.e. to maintain a good level of capability to 
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correctly and precisely capture the information of interest. The following sections describe 
how this study was designed.  
 
 Identification of attributes and levels 
 
First, in order to prepare the scenarios necessary to elicit the preferences, the 
characteristics or attributes that describe the potential products needed to be selected, and 
then appropriate levels could be assigned to each attribute. In addition, both the numbers and 
type of attributes and levels had to be carefully selected to produce an efficient design: it is 
important not to select too many attributes and levels because the dimension, and hence the 
complexity of the experimental design, exponentially increases with these elements, which 
could have potentially negative effects on its capability to capture all the information of 
interest.  
To select the attributes we organised a focus group involving physicians who are 
experts in haemophilia care, pharmacists with experience in this sector, and health 
economists. During the focus group a number of potentially interesting attributes were 
selected: viral safety, time to stop bleeding, possibility of undergoing major orthopaedic 
surgery, risk of anamnestic response, regular use in prophylaxis, time to pain recovery, 
number of injections to stop bleeding, and time to prepare/give/have the injection. The eight 
characteristics identified during the focus group were then submitted, in a pilot study [77], to 
35 subjects (adult patients, paediatric patients’ caregivers, physicians, pharmacists). From the 
results of the pilot study the seven attributes with the highest mean scores were chosen, as 
listed in table 1. An eighth attribute was added in order to make it possible to express 
preferences in terms of WTP. As the Italian National Health Service (NHS) pays for the 
provision of coagulation factor concentrates, it would be unrealistic to ask the respondents to 
imagine a patients’ out of pocket payment to express their WTP for the described products. 
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However, citizens contribute healthcare taxes for the provision of healthcare products and 
services. So, in order to maintain a good level of realism in the scenarios to be presented for 
preferences elicitation, it was decided to ask the interviewees to imagine and to express their 
preferences by taking into account a hypothetical increase of their healthcare taxes, and so 
making it possible for inhibitor patients to receive a treatment with the described product.  
After the attributes were selected, the levels for each attribute were assigned. Further focus 
groups of physicians with experience in the management of patients with inhibitors allowed 
us to select a reasonable number of interesting and realistic levels per attribute, as shown in 
table 1. For the “cost” attribute, the approach used for level selection was to identify 
plausible cost ranges for the scenarios examined during the pilot study (too low or too high 
levels would risk not being seriously taken into consideration by the respondent, with the 
possible consequences of reducing the amount and/or reliability of the responses). 
Participants were asked to express their WTP using additional healthcare taxes for the two 
possible coagulation products presented in the questionnaire. These were described according 
to the attributes selected during the previous focus group. The first was: a ready-to-use 
solution product, with viral safety as a recombinant product, requiring one infusion every 
other day if used in prophylaxis. One infusion was required to stop a bleeding and there was 
no risk of an anamnestic response when infused. The second product presented was a 
lyophilised material which needed to be reconstituted, and had viral safety as a plasma-
derived product. It required two infusions every day if used in prophylaxis and three 
infusions to stop a bleeding, and had a risk of inducing an anamnestic response. After 
describing each product, a list of different possible costs, in terms of healthcare tax increases, 
was presented and the interviewees were asked to choose the amount corresponding with 
their maximum WTP for that product. Overall, the 35 participants in the pilot study reported, 
for the first product presented, an average WTP of €120 per month (from €0 to €800), while 
for the second product a mean of €30 per month (from €0 to €200) was estimated. In 
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addition, the amount of healthcare costs that Italian citizens paid in 2005 was about 8% of 
their income and the monthly per capita gross income was around €1700 [78-80]. 
Accordingly, a per capita cost for healthcare of around €130 per month was estimated. As 
this is compatible in its magnitude to the WTP reported by the respondents of the pilot study, 
it was decided to use this amount as a reference for the assignment of the levels to the cost 
attribute. Hence the following three levels were assigned to the “cost” attribute: 1) there is no 
increase in the healthcare taxes to be paid, i.e. the monthly cost remains around 8% of the per 
capita gross income; 2) healthcare taxes are twice those currently paid, corresponding to an 
increase of €130 per month to be paid by a person receiving an income of €1,700 per month; 
and 3) the healthcare taxes are three times those currently paid, corresponding to an increase 
of €260 per month to be paid from a person earning €1,700 per month.  
 
Experimental design and choice sets generation 
 
Every level of the selected attributes was combined in a factorial experimental design 
to prepare the possible product profiles (or descriptions). It must be noted that combining 26 
X 32 attribute levels in a full factorial design would generate 576 possible profiles: this means 
that each profile obtained from this combination describes hypothetical products. The full 
factorial experimental design actually involves a combination of every possible profile in 
pair-wise choice sets, as combinations of two profiles rather than single profiles were 
presented to be valued: a pair-wise combination of the 576 possible profiles came to a total of 
165,600 different sets to be valued. Although each respondent could value a number of sets, 
it would be very difficult, if not impossible, to submit this number of sets to each one. 
Appropriate statistical approaches were then used to extract a fractional factorial design, i.e. a 
restricted number of choice sets to be valued, in an attempt to keep a good level of 
respondents’ efficiency. In order to achieve this, we aimed to not increase the burden too 
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much and/or difficulty of the exercise for the respondent, and to keep a good level of 
statistical efficiency to capture the amount of information necessary for the purposes of the 
study. A main-effect orthogonal fractional design containing 16 profiles, which allowed the 
main effects for each attribute to be estimated without correlation with each other, was 
selected from a catalogue [81]. In fact, we assumed that interactions among attributes were 
negligible, as main effects typically account for 70-90% of explained variance [82, 83]. The 
16 profiles were then paired to others by applying a fold-over approach [84]. This systematic 
approach pairs each profile with one obtained by switching each attribute level of its 
comparator by one unit, to ensure that each attribute in each choice set maintained a 
minimum overlap: this implies that the respondents make choices by evaluating every 
attribute. Sixteen pair-wise choice sets were finally produced. According to literature on the 
application of DCAs [72] and previous experience in the haemophilia context [74] we 
considered this a reasonable number of choice sets to be submitted to each respondent.  
 
Study sample  
 
In order to obtain preferences from the different points of view relevant for the topic 
of the study, the following individuals were involved: patients with inhibitors or their 
caregivers (one parent or guardian), physicians who are specialists in haemophilia care, and 
pharmacists with experience in managing and delivering coagulation factor products. We 
contacted and invited the physicians and pharmacists to participate in the study. Physicians 
were also asked to enrol patients, or their parents/guardians, if the patients were younger than 
17 years of age. In particular, patients of any age with inhibitors or their parents/guardians, 
who were able to understand the scope of the study and their task and who were willing to 
participate, were enrolled in the study. Parents/guardians were interviewed in the case of 
paediatric patients: in fact, if the patients were aged less than 17 years one of their caregivers 
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was asked to complete the questionnaire and express their own preferences. Each patient or 
parent/guardian was asked to sign an informed consent for his/her participation.  
 
 Ethical issues 
 
This study was conducted in accordance with the principles from the 18th World 
Medical Assembly [85] and all subsequent amendments. Approval for the study was given by 
the Ethical Committee of the coordinating centre, the A. Bianchi Bonomi Haemophilia and 
Thrombosis Centre of the IRCSS Foundation Policlinico, Mangiagalli and Regina Elena 
Hospitals.  
 
Survey instrument and data collection 
 
The participants self-completed a questionnaire at enrolment. The questionnaire 
included an explanation sheet clarifying the scope of the interview and instructions on how to 
complete the task. Specifically, the meaning of each attribute and its levels were explained to 
the participants. They were then invited to imagine, at each choice set (for a total of 16 
choice sets), that they had at their disposal two options of coagulation factor concentrates, 
described according to the reported attribute levels. The participants’ task was to evaluate the 
two options in each choice set and to choose the one option that globally reached the 
maximum value from their point of view. An example of a scenario and choice question is 
shown in figure 1. Information on socio-demographics, on clinical data (e.g. presence of viral 
infections, peak and last inhibitor titre, frequency of haemorrhages, and occurrence of 
surgery in the previous 4 months), on the type of treatment regimen, and on the product used, 
was requested. Physicians and pharmacists were asked to specify their experience with 
inhibitor patients and/or products used in inhibitor patients.  
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Data analyses 
 
DCAs are based on Lancaster’s economic theory of value [86] and on the assumption 
of utility maximization behaviour by the decision-maker, in line with the Random Utility 
Theory (RUT) [87-89]. According to the RUT framework, utility can be separated into a 
systematic or explainable component and a random component: 
 
Uij = Vij + εij 
 
where Uij is the utility derived from choice j by the individual i, V is the systematic, 
measurable component of utility, and ε is the random error, attributable to the component of 
utility that the researcher cannot observe. The assumption is that individual i chooses 
alternative j if the utility derived from that alternative is greater than the utility derived from 
any other alternative k in the choice set (Uij > Uik).  
 
To analyse the data, a logistic regression model was applied to the difference between 
the levels of each attribute. Furthermore, in order to take into account the error component 
attributable to the variability among the respondents, i.e. those who provided multiple 
observations, a random effects model was applied [88]. 
The following linear additive functional form for the systematic component of the 
utility function was assumed: 
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Vj – Vk = hV = β1*hINFECTION + β2 *hTITRE + β3*hINFUS_BLEED +  
+ β4*hTIME_BLEED  + β5*hTIME_PAIN + β6 *hINFUS_PROF + β7 *hSURGERY+ 
+β8*hCOST 
 
where hV is the change in utility in moving from option B (having Vj) to A (with Vk): a 
difference model was in fact estimated and the independent variables included in the model 
were actually the differences between levels of each attribute (as specified with “h”); hence, 
the coefficients (corresponding to the estimates of β) reported in the results section must be 
interpreted as for differences between each attribute level: in other words β1-8 represent the 
taste weights of one unit level of change of the corresponding attribute, i.e. the relative 
importance of each attribute on choice. It is important to be aware of the unit of 
measurement. For instance β1 indicates the value (taste weight) given to having a product 
with a perceived viral risk from a recombinant product over one with a risk from a plasma-
derived product; β3 indicates the mean value given to reducing by 1, within the range of 1 to 
3, the number of infusions necessary to stop the bleeding, and β8 is the mean value given to 
each € within the range from 0 to 260 to be paid as additional healthcare taxes.  
 
The sign of the parameter estimates was observed to verify if the direction of the 
preferences corresponded to the expected one: a priori it was hypothesised that a risk of viral 
infection from a recombinant product is perceived to be lower, and hence would be preferred 
to the risk of a plasma-derived one. A negatively signed regression coefficient was therefore 
expected, according to the codes included in the model, as reported in table 1. Similarly, 
parameter estimates regarding the risk of anamnestic response, the number of infusions to 
stop bleeding, the time to stop the bleeding after the infusion, the time for pain recovery, the 
frequency of weekly infusions in the case of prophylaxis treatment, and the cost were 
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expected to have a positive sign. Finally, the parameter for the possibility of undergoing 
major surgery was expected to have a negative sign. 
 
The MRS between two attributes was estimated in terms of WTP by dividing each 
parameter estimate by the estimate for the cost attribute: these estimates show how much of 
one attribute respondents would be willing to pay for, in terms of healthcare taxes (parameter 
estimate for the cost attribute at the denominator), to have an improvement of another 
attribute (at the numerator).  
 
In order to understand which attribute contributes more to the utility of the drugs 
under study, their relative importance (RI) was estimated by computing the ratio of the utility 
given to each attribute, within the range of the levels assigned, to the sum of the utilities 
assigned to the level ranges of all the attributes included in the experiment.  
 
All the analyses were conducted by splitting the sample into three subgroups, in order 
to identify and investigate the different preferences between the points of view of the patients 
(or their caregivers), the physicians, and the pharmacists.  
 
Although discrete choice exercises imply that people make trade-offs between the 
submitted attributes according to their different levels, this does not always happen. In fact, 
in some cases the respondent shows apparent unwillingness to accept reductions in one 
attribute in return for improvements in others, exhibiting the so-called lexicographic 
preferences with respect to the attribute he/she prefers. In this case the respondent always 
chooses that attribute in every choice set presented, without trading between the other ones. 
We tested also whether lexicographic preferences were present among the participants in this 
study. 
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The results of the analyses were considered statistically significant if p<0.05, with 
two-tailed tests. Analyses were conducted with STATA version 9.0 and with SPSS version 
15.0.  
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RESULTS 
 
Description of the study sample 
 
A total of 101 people were enrolled and interviewed from different regions of Italy: 
25 adult patients, 12 paediatric patients’ caregivers, 39 physicians, and 25 pharmacists.  
 
Both adults and caregivers of paediatric patients were enrolled in the study. A full 
description of the characteristics of the patients is reported in table 2.  
 
Twenty-one (84%) pharmacists had experience in preparing and/or dispensing 
coagulation factor concentrates for patients with inhibitors. Thirty-four physicians (87%) had 
experience in prescribing and/or preparing and/or administrating coagulation factor 
concentrates for patients with inhibitors. 
  
Preferences towards coagulation factor concentrate characteristics 
 
A total of 1614 observations (choices) were obtained from the discrete choice 
exercises. Only two out of 101 respondents skipped one of the 16 choice sets submitted, with 
a response rate of 99.9%. The high response rate suggests a good level of feasibility of the 
exercises submitted to the interviewees.  
Table 3 presents the regression results from the overall sample. According to the 
coefficient signs the theoretical validity of the model was confirmed. In particular, the 
respondents preferred a product with a level of safety from risk of viral infection as the one 
attributed to a recombinant product, when compared with a product with viral safety as the 
one assigned to a plasma-derived product. They preferred a product with no risk for the 
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inhibitor titres increasing, that requires a lower number of infusions, a lower time to stop 
bleeding after the infusions, a lower time to pain recovery, a lower number of infusions per 
week in case it is used prophylactically, that allows the patient to undergo major surgery, and 
has a lower cost in terms of additional healthcare taxes. The statistical significance of the 
parameter estimates (p=0.006 in the regression coefficient for frequency of infusions in 
prophylaxis regimen, p<0.0001 in every other attribute) show that every attribute included in 
the scenarios is important to the interviewees.  
 
When looking at the results from each subgroup of respondents, i.e. the patients or 
their caregivers, the physicians, and the pharmacists, the data show that the direction of 
preferences did not change among these subgroups; however, the relative importance 
assigned to some attributes was different, as shown in table 4 and in more detail in figure 2. 
Three attributes, namely time to stop the bleeding, possibility of undergoing major surgery, 
and cost were found to be statistically significant by every subgroup. Figure 2 shows the 
impact of each attribute, within the range of levels included, relative to the importance of all 
the attributes included in the scenarios. As a point of reference, the RI would be 100/8 = 
12.5% if all eight attributes were of equal importance.  
 
For patients (or their caregivers) the most important factors affecting treatment 
decision were: increase in healthcare taxes (RI=21.0%), risk of anamnestic response 
(RI=20.3%), the possibility of undergoing major surgery (RI=17.9%), and perceived viral 
safety (RI=17.7%). For physicians the most important factors were: increase in healthcare 
taxes (RI=25.7%), risk of anamnestic response (RI=18.2%), number of infusions to stop 
bleeding (RI=14.2%), and the possibility of undergoing major surgery (RI=13.2%). For the 
pharmacists the most important factors were: increase in healthcare taxes (RI=26.8%), time 
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to stop bleeding (RI=19.8%), time to pain recovery (RI=14.4%), and the possibility of 
undergoing major surgery (RI=13.4%). 
 
It is particularly interesting to note that every subgroup assigned the highest relative 
value to the increase of healthcare taxes. Another very interesting finding is the high value 
given by the patients/caregivers and physicians to the risk of anamnestic response, in contrast 
with the pharmacists’ opinion, and the high value attributed to the perceived viral safety 
given by the patients/caregivers, followed by the pharmacists, but not by the physicians.  
 
It is also worth noting that 16 respondents (five adult patients, five caregivers, three 
physicians, and three pharmacists) showed a non-trading attitude toward some characteristics, 
i.e. they made their choices by always taking into account the same attribute and skipping a 
trade-off between the attributes included in the scenario. In particular three physicians, two 
patients, and two caregivers always preferred the option with no risk of anamnestic response; 
six patients and one pharmacist always chose according to the product’s viral safety. One 
pharmacist always chose the options allowing the patient to undergo surgery, while another 
pharmacist always chose the products requiring 12 instead of 24 hours to stop the bleeding 
after infusion.  
 
Willingness to Pay 
 
The different relative values given by the three categories of respondents to each 
characteristic corresponded to different WTPs, as shown in Table 4. In particular, the 
patients/caregivers and the physicians would on average be willing to accept an increase of 
taxes up to €260 and €200 per month, respectively (by assuming a monthly gross income of 
€1,700), to make available a product with no risk of anamnestic response, assuming all other 
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things were equal. Pharmacists would on average be willing to pay around €20 per month. 
The patients/caregivers would pay up to €229 for a product allowing patients to undergo 
major (e.g. orthopaedic) surgery, the physicians €145, while the pharmacists would on 
average pay €115 per month. Regarding the perceived viral safety, the patients/caregivers and 
pharmacists would be willing to accept an increase of taxes up to €226 and €107, 
respectively, while the physicians would on average pay around €33 per month to have a 
recombinant versus a plasma-derived product. The patients/caregivers and the pharmacists 
would on average pay up to €15 extra per month for a product that reduced the time to stop a 
bleed by one hour, while the physicians would pay around €10 per month. The 
patients/caregivers would be willing to pay €90 extra per month to have a product requiring 
one infusion every other day instead of one requiring one infusion every day; however, the 
physicians would pay €48 and the pharmacists €26 per month. While the physicians and 
pharmacists would pay €31 per month for a product that reduced time to pain recovery by 1 
hour, the patients showed a lower WTP for this attribute, corresponding to €7 per month in 
additional healthcare taxes. Finally, while the physicians would pay €78 per month for a 
product requiring one infusion less to stop the bleeding, the pharmacists would pay €34 and 
the patients/caregivers would pay just €1 per month.  
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DISCUSSION 
 
 Summary of results and main potential implications 
 
To our knowledge this is the first work comparing the value given by patients (or their 
caregivers), physicians, and pharmacists to the different characteristics of coagulation factor 
concentrates used for the treatment of haemophilia patients with inhibitors. Not only outcome 
attributes (i.e. viral safety, risk of anamnestic response, the time to stop a bleeding, time to 
alleviate the pain, and possibility of undergoing major surgery), but also process attributes 
(frequency of infusions to stop a bleeding or to follow a prophylaxis regimen) and cost are 
considered important for a product used in patients with inhibitors. Cost, in terms of 
additional healthcare taxes, was the most important attribute to every group. However, high 
monetary values were added to a number of characteristics, above all to the risk of 
anamnestic response by patients/caregivers and physicians; to the possibility of undergoing 
surgery by every respondent group; and to the viral safety assigned to the products by the 
patients/caregivers and the pharmacists. 
Historically, the objective of hemophilia treatment was to survive the disease; 
however, hemophilia is no longer considered to be a life-threatening condition, as advanced 
health technologies have improved patients’ life expectancy [90] and allowed to keep 
relatively good levels of HRQoL [e.g., 49, 53, 57]. Nonetheless, much work is still necessary 
to optimize patients’ health, but on the other hand there is still considerable uncertainty 
regarding the issue of which therapeutic strategy provides optimal benefit. Among the most 
crucial issues to be considered, resource constraints often limit access to the most effective 
treatment options. In an era of limited resources competing with potentially unlimited needs 
and demands, it is necessary to make decisions on how, where and for whom to allocate these 
resources. 
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Appropriate investments must be identified and applied if we are to achieve efficient 
management of hemophilia patients. Investments incur cost and can be perceived as too 
expensive, at least in the short-term; however, appropriate investments should be considered 
as opportunities to improve patients’ overall health and wellbeing. Furthermore, 
implementation of appropriate investments could also translate into economic benefits from 
the perspective of patients, their carers, the healthcare system, and society as a whole. In 
order to make rational decisions about which treatment strategies to apply, the costs 
associated with such treatments should be considered together with the benefits they allow 
and the potential benefits that may be lost if they are not used.  
Taking into considerations these several and different aspects also depend on decision 
makers’ opinions and preferences, which depend on different factors, not always or only 
attributable to clinical issues. Some opinions are inherent to the products or services 
themselves, but others are related to other aspects, such as patients’ needs, experiences and 
expectations. In haemophilia care, unlike those in some other contexts, preferences from 
different actors, including patients, occupy a primary role in the decision-making process.  
Against some expectancies, economic issues are considered important as well by 
people involved in haemophilia: this study in fact showed that although the treatment for 
haemophilia is paid for by the Italian NHS, every group of respondents showed awareness of 
the potential cost to them that a product could generate.  
The results of this study are relatively comparable with those of another recently 
published study [91]. The focus of the Lee study was only on physicians’ preferences: 
according to a group of US specialist physicians, 64% of the relative importance was given to 
the time and number of infusions required to stop bleeding, the time required to alleviate 
pain, the anamnestic response, and the risk of viral infections. Except for the perceived risk 
of viral infections, these attributes are also among the most important attributes in the present 
study. Interestingly, the cost of medication was one of the lowest important characteristics in 
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the Lee study. Differences in the results of the two studies may be explained by a number of 
reasons. One possible reason is attributable to the different scenarios presented to the 
participants, with different characteristics and different levels assigned to each characteristic: 
for instance, the cost attribute was expressed in a completely incomparable way in the two 
studies. With this in mind, it must be noted that the options proposed in the two studies were 
the result of previous research conducted to construct the scenarios according to their 
potential interest and realism in the target context. For instance, the choice to consider 
healthcare taxes as a proxy for the cost attribute may not be directly applicable in some 
countries, e.g., those that have a private insurance system to finance healthcare. Other 
differences in the results could also be due to the differing experiences of physicians in their 
countries. In considering these factors, we believe that the key information from the study 
regarding the relative value given to characteristics of each product used to treat inhibitor 
patients, from the different people involved, are valid and reliable for other healthcare 
systems where the study population is similar to this one. 
 
A large number of considerations have to be taken into account when choosing the 
treatment for each patient. They are based on safety, effectiveness, costs, experiences and 
opinions. According to a panel of haematologists who discussed treatment choices for 
inhibitor patients [62]. They specified that a trade-off between different characteristics of the 
products or treatment regimen is necessary when choosing the strategy to be adopted. 
However, a lack of consensus exists on the most appropriate therapeutic strategy to be 
adopted, while economic issues can be the cause of barriers for the application of the most 
appropriate therapeutic options [58-65] . Increasing the knowledge and awareness of the 
preferences of the different parties in the decision-making process, i.e. physicians, budget 
holders, as well as patients or their carers, is a primary objective that should be pursued to 
improve the benefits of the treatment. The results of the present study can help to reach this 
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objective, in particular, the information provided by this work can be useful for optimal 
decision making, when taken into account with other factors based on safety, clinical 
effectiveness, patients’ quality of life, and costs. A comprehensive evaluation of all of these 
components can allow the overall value of the different treatment options to be recognised, 
and so facilitate the identification of the most appropriate treatment for each situation. 
 
Study limitations 
 
Some potential limits can be ascribed to this study. First, 36% of the respondents 
showed a non-trading attitude, i.e. they always chose according to the same characteristic, 
giving up a possible trade-off between the other ones. Although this attitude can be attributed 
to a real unwillingness to trade between attributes, i.e. a very strong preference toward only 
one attribute, “at any cost”, another reason for this phenomenon could be ascribed to the 
complexity of the exercises. It has been suggested that the more complex a choice becomes in 
terms of the number of options and the variability within options, the less likely people are to 
engage in compensatory decision making and instead adopt a lexicographic ordering of 
attributes [92]. We were aware of the possible difficulties that can be encountered during the 
completion of a discrete choice exercise and during the design paid special attention to this 
aspect. For example, in order to improve the efficiency of the design [76] and to reduce the 
burden of the exercise, we selected the number and type of both attributes and levels per 
attribute that would make the scenarios as feasible, acceptable, realistic, and interesting as 
possible.  
Some criticisms may arise because of the decision to estimate the monetary values 
assigned to the attributes of a coagulation factor concentrate, which could be considered 
unrealistic, and therefore not appropriate within the context examined. The approach of WTP 
is in fact not simple to apply. One reason for this is that neither the patients, nor the 
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physicians or the pharmacists actually pay for the provision of coagulation factor 
concentrates, because in the Italian healthcare system the NHS completely covers the cost of 
these products. However, allowances were made for this during the design of this study, as 
specified in the methods section. Furthermore, the subjects participating in the study assigned 
a high relative importance to the possibility of having to pay higher healthcare taxes. 
However, they also showed a willingness to pay higher taxes so that better coagulation factor 
concentrates could be available to inhibitor patients. 
Finally, some criticisms may be attributed to the size of the sample. It is, however, 
important to note that the number of patients or caregivers (37), physicians (39), and 
pharmacists (25) should actually be considered relatively big, if framed within the target 
population, which in Italy comprises around 300 patients. Furthermore, it is important to note 
that every participant contributed 16 observations each (i.e. 16 choices), to a total of more 
than 1600 observations.  
 
 
Conclusion and considerations for future investments 
 
Inhibitors constitute a potentially serious obstacle to haemophilia treatment. Strategies 
like the implementation of ITI or the use of bypassing agents has proved successful, but this 
has been achieved through apparently very costly investments. However, the cost of these 
investments must be considered together with the benefits they actually bring – benefits that 
can depend not only on the characteristics of the patients, but also on their preferences, 
expectations, and on opinions and experiences of the other parties involved in the decision-
making.  
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The present study enabled us to estimate the relative importance and magnitude of 
value assigned to the different characteristics of coagulation factor concentrates according to 
different points of view.  
Taking into consideration knowledge on these preferences, together with other aspects 
like the patients’ clinical needs, can help to optimise decisions on the use of different 
products (e.g. rFVIIa versus aPCC) and treatment regimens (e.g. prophylaxis versus on-
demand) in this challenging patient population.  
 
Next efforts to be done by the health care systems, to optimally manage people with 
haemophilia, must focus on reducing the consequences attributable to the disease in order to 
improve patients’ health. Reducing the costs of managing hemorrhages and arthropathy, 
performing surgery and satisfying other clinical needs should be considered a further 
objective. Decision-making in hemophilia care involves a complex interaction between 
different parties, i.e. physicians, patients, and budget holders, each of which carries their own 
set of needs (e.g. patients’ clinical status; treatment costs), experiences, expectations, and 
preferences, all influenced by the role that these parties play in the healthcare system []. In 
order to allow for appropriate decisions, every relevant aspect must be analyzed.  
For instance, prophylaxis is recognized for its potential benefits in terms of bleeding 
reduction, prevention of future disabilities, and consequent improvement of patients’ health 
and wellbeing. Subsequently, further benefits could also be expected from both the patients’ 
and society’s point of view, as a reduction in the costs of managing complications and 
productivity could be expected. Prophylaxis can be a particularly challenging regimen, and 
might not be applicable to all inhibitor patients [58] In addition, prophylaxis appears to be 
very expensive, at least in the short term. Information on both present and future costs and 
benefits (from the perspective of patients, their carers and the healthcare system), is thus 
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necessary to understand the relative value of the compared options and then to make rational 
decisions on which one to apply.  
 
Hemophilia is a chronic, lifelong condition. The management of this disease and 
related consequences should be considered as a long-term investment; present and future 
benefits and associated costs should all be taken into account when evaluating and comparing 
treatment options. Generally speaking, making investments incurs costs, with the precise 
objective of gaining benefits. Not making investments can apparently incur less or no cost; 
however, questions should be asked about the consequences that can be expected from not 
making investments, in terms of present and future benefits and costs.  
 
Conducting appropriate health technology evaluations, including both clinical and 
economic  issues, is strongly encouraged in order to gain all the information necessary for 
making decisions that lead to efficient investments. 
 
Economic evaluations are techniques applied to estimate and compare benefits and 
costs derived from the application of alternative options, with the objective of informing 
decision-makers about the most efficient one and hence contributing to appropriate decisions.  
Health economics, which involves the application of the principles and concepts of 
economics [93] to the healthcare sector, is therefore an aid to decision-making for healthcare 
interventions; it is not aimed at containing costs, but rather at rationalizing the allocation of 
the available resources to maximize the benefits derived from their use. Furthermore, the 
application of economic principles to the evaluation of healthcare interventions is 
complementary – not an alternative – to the assessment of their quality, safety and 
effectiveness. 
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Table 1: Attributes and levels description 
Attributes (labels) Levels: codes (as included in the model) and description 
Perceived risk of viral infection (INFECTION) (0) As from a plasma-derived product (1) As from a recombinant product 
Risk of anamnestic response (TITRE) (0) No (1) Yes 
Number of infusions to stop bleeding (INFUS_BLEED)  
(1) 1 infusion  
(2) 2 infusions 
(3) 3 infusions 
Time to stop bleeding (TIME_BLEED) (12) 12 hours (24) 24 hours 
Time to pain recovery (TIME_PAIN) (2) 2 hours (6) 6 hours 
Number of weekly infusions if used in prophylaxis regimen (INFUS_PROPHY) (0) 1 infusion every other day (1) 1 infusion every day 
Possibility of undergoing major surgery (SURGERY) (0) No (1) Yes 
Increase of healthcare taxes (COST) 
(0) No additional contribution in healthcare taxes required 
(130) Having to pay double the current taxes, i.e. €130 more 
assuming a monthly gross income of €1,700  
(260) Having to pay triple the current taxes, i.e. €260 more 
assuming a monthly gross income of €1,700  
Explanation of the meaning of each attribute: INFECTION refers to viral risk of infection as that perceived from a highly purified plasma-derived concentrate 
versus a risk as perceived from a recombinant product; TITRE refers to the presence versus absence of possibility for the titre of inhibitors to increase after the 
infusion; INFUS_BLEED refers to the number of infusions necessary to stop a bleeding; TIME_BLEED refers to the time necessary to stop a bleeding after the 
infusion; TIME_PAIN refers to the time necessary to stop pain; INFUS_PROF refers to the number of necessary infusions in a prophylactic regimen; SURGERY 
refers to the possibility of undergoing a major intervention, like joint implantation, versus not having this possibility. Finally COST refers to the increase in 
healthcare taxes to the Italian citizens in order for inhibitor patients to be able to receive the products described. 
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Table 2: Description of the patients 
Description Adult patients (N=25) Paediatric patients (N=12) 
Age: mean (SD) 
        (median; min-max) 
41.4 (11.0) 
(39.9;17.0-62.0) 
8.2 (4.6)
(7.7; 2.0-16.0)
Patients with severe haemophilia A: N (%) 25 (100)   12 (100) 
Patients with viral infections: N(%) 
Hepatitis C infection 
Hepatitis B infection 
HIV 
 
21 (84.0) 
4 (16.0) 
4 (16.0) 
0.0
0.0
0.0
Inhibitors titre (BU/mL):  
Historical peak titre 
                                          
 
mean (SD) 
median (min-max) 
 
1,040.0 (2,642.0) 
164.0 (5.0-13,000.0) 
1,040.0 (2,642.0)
167.5 (6.0-16,400.0)
Last recorded titre:  
                                                              
mean (SD) 
median (min-max) 
85.0 (206.0) 
10.0 (0.0*-800.0) 
67.6 (150.4)
15.0 (1.0-516.0)
Patients with haemorrhages 4 months before the interview N (%):  0 
1-2 
3.5 
> 6 
2 (8.0) 
8 (32.0) 
7 (28.0) 
8 (32.0) 
2 (16.7) 
2 (16.7) 
2 (16.7) 
6 (50.0) 
Patients undergoing surgery in the previous 4 months N(%) 3# (12.0) 0
Treatment regimen followed at the time of the interview: N (%) of patients 
Prophylaxis 
Immunotolerance 
On demand 
 
5 (20.0)  
4 (16.0) 
16 (64.0) 
2 (16.7) 
5 (41.7) 
5 (41.7) 
Coagulation factor used in the 4 months before the interview: N (%) of patients 
rFVIIa 
aPCC  
Recombinant FVIII 
Plasma-derived FVIII 
Patients using more than one product: N (%) 
 
15 (60.0) 
10 (40.0) 
1 (4.0) 
5 (20.0) 
5 (20.0) 
 
8 (66.7) 
4 (33.3) 
5 (41.7) 
0
5 (41.7) 
* Although these patients had no inhibitors according to the last detection before the interview they were acknowledged and treated as inhibitor 
patients. 
# 1 patient underwent ankle arthroscopy, 1 underwent arthrocentesis, and 1 underwent surgery for scrotal-inguinal hernia 
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Table 3: Results of the main model, showing the results from the whole sample 
Attribute Coefficients (β estimates)° 
and Standard Errors 
P values 
INFECTION -0.334 (0.060) 0.000 
TITRE 0.526 (0.057) 0.000 
INFUS_BLEED 0.154 (0.044) 0.000 
TIME_BLEEDS 0.038 (0.005) 0.000 
TIME_PAIN 0.081 (0.015) 0.000 
INFUS_PROPHY 0.159 (0.057) 0.006 
SURGERY -0.515 (0.061) 0.000 
COST 0.003 (0.000) 0.000 
   
Number of observations 1614  
Number of subjects 101  
Rho 0.006  
Log Likelihood# -932.564  
McFadden R2 * 0.1669  
Chi-square (p value)  297.13 (<0.0001)  
° Coefficients are computed for the difference between the levels of each attribute. For instance, the coefficient of “INFECTION” represents the taste weight for moving from a 
recombinant to a plasma-derived product, every other attribute assumed to be equal. Regarding domains coded as continuous variables (INFUS_BLEED, TIME_BLEED, 
TIME_PAIN, COST), the coefficient represents the taste weight for one unit of change in the corresponding attribute level. 
The sign indicates the direction of preferences: in case of “INFECTION” the negative sign means that respondents preferred recombinant (coded as 1) over plasma-derived 
products (coded as 0); regarding COST, the positive sign of coefficients means that respondents preferred lower over higher cost. # Logistic regression uses maximum likelihood 
approach to estimate parameters 
* Pseudo R2 (McFadden R2) is a measure of the overall model goodness-of-fit. It is defined as 1-(LL/LL0), where LL is the value of the log-likelihood function evaluated at the 
estimated parameters, LL0 is the value of the log-likelihood function for a base model that only contains the intercept (constant) 
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Table 4: Results of the segmentation model, showing the results from each sub-sample  
Attribute Patients and caregivers Physicians Pharmacists 
 Coefficients° 
(p values) 
WTP (95% CI) 
 
Coefficients°  
(p values) 
WTP (95% CI) Coefficients° 
(p values) 
WTP (95% CI) 
INFECTION -0.439(0.000) 226.37 (88.56, 364.17) -0.151 (0.161) 32.77 (-12.97, 78.51) -0.482(0.000) 107.24 (53.11, 161.38) 
TITRE  0.503 (0.000) 259.80 (81.08, 438.51)  0.919 (0.000) 199.67 (128.98, 270.35)  0.085 (0.484) 18.80 (-36.16, 73.76) 
INFUS_BLEED  0.002(0.971) 1.26 (-67.49, 70.01)  0.359 (0.000) 77.92 (39.93, 115.91)  0.154 (0.120)  34.41 (-7.64, 76.47) 
TIME_BLEED  0.028 (0.000) 14.57 (4.40, 24.73)  0.042 (0.000) 9.07 (5.23, 12.90)  0.064 (0.000)  14.13 (9.02, 19.25) 
TIME_PAIN  0.014(0.562)  7.14 (-18.66, 32.94)  0.142 (0.000) 30.84 (15.45, 46.23)  0.139 (0.000)  30.89 (13.31, 48.47) 
INFUS_PROPHY  0.174(0.055)  90.01 (-11.60, 191.62)  0.221 (0.036) 48.02 (2.16, 93.88)  0.117 (0.330)  26.05 (-26.19, 78.30) 
SURGERY -0.444(0.000)  229.27 (82.70, 375.85) -0.669 (0.000) 145.47 (89.86, 201.08)  0.518 (0.000)  115.26 (53.66, 176.87) 
COST  0.002(0.000)  /  0.005 (0.000) /  0.004 (0.000) / 
  
No. of observations 1614   
Number of subjects 101   
Rho 0.006   
Log Likelihood# -892.085   
McFadden R2 * 0.202   
Chi-square (p value)  303.93 (p<0.0001)  
° Coefficients are computed for the difference between the levels of each attribute. For instance, the coefficient of “INFECTION” represents the taste weight for moving from a 
recombinant to a plasma-derived product, every other attribute assumed to be equal. Regarding domains coded as continuous variables (INFUS_BLEED, TIME_BLEED, 
TIME_PAIN, COST), the coefficient represents the taste weight for one unit of change in the corresponding attribute level. The sign indicates the direction of preferences: in case 
of “INFECTION” the negative sign means that respondents preferred recombinant (coded as 1) over plasma-derived products (coded as 0); regarding COST, the positive sign of 
coefficients means that respondents preferred lower over higher cost.  
# Logistic regression uses maximum likelihood approach to estimate parameters 
* Pseudo R2 (McFadden R2) is a measure of the overall model goodness-of-fit. It is defined as 1-(LL/LL0), where LL is the value of the log-likelihood function evaluated at the 
estimated parameters, LL0 is the value of the log-likelihood function for a base model that only contains the intercept (constant) 
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Figure 1: Example of a choice set presented to the respondents 
ATTRIBUTES  TREATMENT A TREATMENT B 
Perceived risk of viral infection  As a plasma-derived concentrate As a recombinant factor concentrate 
Risk of anamnestic response  Yes No 
Number of infusions to stop bleeding   1 infusion 2 infusions  
Time to stop bleeding  12 hours 24 hours 
Time to pain recovery  2 hours  6 hours 
No of weekly infusions if used in prophylaxis 1 infusion every other day 1 infusion every day 
Possibility of undergoing major surgery  No Yes 
Healthcare taxes increase  None Doubling health care taxes 
 
Which product would you choose, A or B? 
A ? B ? 
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Figure 2: Relative importance assigned by each sub-group of respondents to each attribute.  
Relative Importance of characteristics according to Patients' or Caregivers' 
Preferences
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